Rosetta Genomics Ltd. eliminated the position of chief commercial officer from the company.
As a result, the company terminated Mark Willig from employment.
Discover more about S&P Global’s offerings
Rosetta Genomics eliminates chief commercial officer position
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Rosetta Genomics Ltd. eliminated the position of chief commercial officer from the company.
As a result, the company terminated Mark Willig from employment.